ID
28852
Beschrijving
Study ID: 100723 Clinical Study ID: AXR100723 Study Title: A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Compare the Efficacy of Formulation X and AVANDIA™ (8mg OD) in Subjects with Type 2 Diabetes Mellitus Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia; Avandia XR; Avandia XR,Rosiglitazone XR,Avandia; Rosiglitazone XR Study Indication: Diabetes Mellitus, Type 2 Documentation part: Additional Forms - Investigational Product
Trefwoorden
Versies (1)
- 08-02-18 08-02-18 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
8 februari 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Efficacy of Formulation X and AVANDIA in Subjects with Type 2 Diabetes Mellitus 100723
Additional Forms - Investigational Product
- StudyEvent: ODM
Similar models
Additional Forms - Investigational Product
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0180098 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,3])
C0332307 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,2])
C0013072 (UMLS CUI [1,3])
C0808070 (UMLS CUI [1,2])
C0806020 (UMLS CUI [1,2])